Published in Medical Devices and Surgical Technology Week, September 4th, 2005
In a recent study, endocrinologists in the Netherlands sought to determine "whether the growth hormone (GH) response after the subcutaneous administration of 50 microg of octreotide (acute octreotide test) has any predictive value for long-term IGF-I normalization with Sandostatin LAR."
"Twenty four therapy-naive patients with active acromegaly were studied," noted W.W. de Herder and coauthors working at the Erasmus Medical Center. They found that a ">75% GH decrease in the acute octreotide test predicted long-term IGF-I normalization with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week